Rituximab primarily targets an intra-clonal BCR signaling proficient CLL subpopulation characterized by high CD20 levels

Leukemia. 2018 Sep;32(9):2028-2031. doi: 10.1038/s41375-018-0211-0. Epub 2018 Jul 20.

Gabriela Pavlasova^{1

2}, Marek Borsky², Veronika Svobodova^{1

2}, Jan Oppelt¹, Katerina Cerna^{1

2}, Jitka Novotna², Vaclav Seda^{1

2}, Miloslava Fojtova³, Jiri Fajkus³, Yvona Brychtova², Michael Doubek², Sarka Pospisilova², Jiri Mayer², Marek Mraz^{4

5}

¹ Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
² Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
³ Mendel Centre for Plant Genomics and Proteomics, Central European Institute of Technology and Faculty of Science, Masaryk University, Brno, Czech Republic.
⁴ Molecular Medicine, Central European Institute of Technology, Masaryk University, Brno, Czech Republic. marek.mraz@email.cz.
⁵ Department of Internal Medicine, Hematology and Oncology, University Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic. marek.mraz@email.cz.

No abstract available

Publication types